Comparative trials of live attenuated and detergent split influenza virus vaccines.
Comparative clinical trials of live attenuated and detergent-split subunit influenza virus vaccines were undertaken with 1048 volunteers in Western Australia. Volunteers were divided into three main groups, each of which received either live virus vaccine or a saline control administered intranasally, or subunit vaccine injected subcutaneously. No differences were recorded between the three groups in their post-vaccination symptoms. Serum samples were collected at various times up to 50 weeks after vaccination, and antibody titres were measured by haemagglutination-inhibition (HI) tests and, for 231 volunteers, by virus neutralization tests. The two vaccines were almost equivalent in inducing seroconversion in vaccinees with pre-trial HI titres of 96 or less, but the subunit vaccine stimulated a higher geometric mean HI antibody titre. The longevity of the HI antibody response was greater for the live virus vaccine. The height of the response and the longevity of neutralizing antibody were the same for both vaccines. Both vaccines provided a high degree of protection against epidemic A/England/42/72 influenza, and some protection against A/Port Chalmers/1/73 influenza.
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D001315:Australia; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects / Q000592:standards* / Q000627:therapeutic use; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009975:Orthomyxoviridae / Q000276:immunology* / Q000302:isolation & purification; D010919:Placebos; D014613:Vaccines, Attenuated / Q000592:standards*
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D010919:Placebos; D014613:Vaccines, Attenuated